Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Severe Keratitis

Trial Profile

A Multicenter, Open-label Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Severe Keratitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Keratitis
  • Focus Therapeutic Use
  • Sponsors Mallinckrodt Inc.

Most Recent Events

  • 20 May 2021 Results assessing the quality of life (QoL) and symptomatic improvements of treatment with Corticotropin Injection in refractory severe noninfectious keratitis, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
  • 03 May 2021 According to a Mallinckrodt media release, further data will be shared at the upcoming virtual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting.
  • 03 May 2021 According to a Mallinckrodt media release, the full results were presented in a poster at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top